Blog
RSS FeedPosted by Michael Wonder on 10 Jul 2019
FDA announces new efforts to expedite generic drug development and marketing to improve patient access to medicines
10 July 2019 - Today, the U.S. FDA announced a draft guidance, Harmonizing Compendial Standards With Drug Application Approval Using the ...
Posted by Michael Wonder on 01 Jul 2019
Delays a matter of life and death
1 July 2019 - The shocking news that Aussie cancer patients are facing long waits for essential medicines is cause for ...
Posted by Michael Wonder on 30 Jun 2019
Why it takes five years for life saving medicines to get funded
30 June 2019 - Cancer patients are waiting up to five years to access life-saving medicines as spending on the ...
Posted by Michael Wonder on 22 Jun 2019
Delayed patient access to innovative medical technologies in South Korea: a lead-time analysis of reimbursement coverage determinations
20 June 2019 - Timely access to innovative medical technologies driven by accelerated patient access pathways can substantially improve the health ...
Posted by Michael Wonder on 22 Jun 2019
Should the FDA speed up or slow down approval of new cancer drugs?
21 June 2019 - Earlier this month, the FDA announced the creation of Project Facilitate. ...
Posted by Michael Wonder on 19 Jun 2019
Game-changing cancer drugs which can attack all tumours will be fast-tracked by NHS
19 June 2019 - Game-changing cancer drugs which can attack all types of tumour will be fast-tracked by the NHS, ...
Posted by Michael Wonder on 19 Jun 2019
Atomoxetine – delay in change of funded brand and open access
19 June 2019 - PHARMAC is advising all interested parties that there will be a delay in the listing of ...
Posted by Michael Wonder on 17 Jun 2019
Updated PBAC Calendar and publication of Stage 1 PBS Process Improvements – Procedure Guidance and supporting documents
17 June 2019 - The Department of Health and Medicines Australia have been working since late 2017 to deliver on ...
Posted by Michael Wonder on 04 Jun 2019
US FDA review for Scenesse extended by three months
3 June 2019 - The FDA sets new goal date of 6 October 2019 to complete review and issue risk-benefit decision. ...
Posted by Michael Wonder on 20 May 2019
Korean Government to reduce biopharmaceutical approval period to half
20 May 2019 - The Korean government plans to reduce by half the current one and a half years of ...
Posted by Michael Wonder on 14 May 2019
Helping Canadians get faster access to the prescription drugs they need to live healthier lives
13 May 2019 - Government of Canada consults on new approach to fast-track the review of treatments for serious, rare ...
Posted by Michael Wonder on 10 May 2019
Speed up cancer funding, ALP told
11 May 2019 - The head of Australian drug company Specialised Therapeutics, Carlo Montagner, has warned that Bill Shorten’s cancer ...
Posted by Michael Wonder on 23 Apr 2019
Canadians will wait longer for new medicines if Health Canada gets its way
23 April 2019 - The intention is to lower prices; the net result will likely be longer wait times before new ...
Posted by Michael Wonder on 23 Apr 2019
Additional embargo period following revised CDEC recommendations
17 April 2019 - Effective immediately, CADTH has revised its procedures for the CADTH Common Drug Review to permit an ...
Posted by Michael Wonder on 15 Apr 2019
PHARMAC's early access scheme needs work - Prime Minister Jacinda Ardern
16 April 2019 - Prime Minister Jacinda Ardern admits work needs to be done on PHARMAC's early access scheme, but ...